Literature DB >> 8838447

sigma Receptor antagonists block the development of sensitization to cocaine.

H Ujike1, S Kuroda, S Otsuki.   

Abstract

The effects of putative sigma receptor antagonists, BMY-14802 (alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine), rimcazole and SR-31742A (cis-3-(hexahydroazepin-1-yl)1-(3-chloro-4- cyclohexylphenyl)propene-1), on the development of behavioral sensitization induced by repeated administration of cocaine were investigated. Acute intraperitoneal injection of 15 mg/kg cocaine in rats induced moderate hyperactivity which mainly consisted of sniffing and rearing. These acute effects of cocaine were hardly affected by co-administration of the sigma receptor antagonists, except that BMY-14802 enhanced, but not significantly cocaine-induced locomotion. While repeated cocaine administration induced a progressive increase in stereotyped behaviors and resulted in sensitization, every sigma receptor antagonists tested attenuated the development of sensitization to cocaine. These prophylactic effects of sigma receptor antagonists against cocaine-induced sensitization were confirmed by the challenge test with cocaine alone after an abstinence. These results were consistent with results of our previous study which revealed that BMY-14802 blocked the sensitization to methamphetamine, another psychostimulant. Therefore, sigma receptors play a crucial role in the development of the psychostimulant-induced sensitization phenomenon, which is a pharmacological model of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8838447     DOI: 10.1016/0014-2999(95)00693-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls.

Authors:  Roman Stefanski; Zuzana Justinova; Teruo Hayashi; Minoru Takebayashi; Steven R Goldberg; Tsung-Ping Su
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

3.  Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine.

Authors:  Rae R Matsumoto; Su-Min Li; Jonathan L Katz; William E Fantegrossi; Andrew Coop
Journal:  Drug Alcohol Depend       Date:  2011-03-21       Impact factor: 4.492

4.  Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents.

Authors:  Nidhi Kaushal; Matthew J Robson; Harsha Vinnakota; Sanju Narayanan; Bonnie A Avery; Christopher R McCurdy; Rae R Matsumoto
Journal:  AAPS J       Date:  2011-04-15       Impact factor: 4.009

5.  Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice.

Authors:  J Kitanaka; N Kitanaka; T Tatsuta; F S Hall; G R Uhl; K Tanaka; N Nishiyama; Y Morita; M Takemura
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

6.  The sigma receptor: evolution of the concept in neuropsychopharmacology.

Authors:  T Hayashi; Tp Su
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

Review 7.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.

Authors:  Melanie A Paquette; Elizabeth G Brudney; Daniel B Putterman; Charles K Meshul; Steven W Johnson; Stephen Paul Berger
Journal:  Neuroreport       Date:  2008-01-08       Impact factor: 1.837

9.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.